<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01152164</url>
  </required_header>
  <id_info>
    <org_study_id>125/08</org_study_id>
    <nct_id>NCT01152164</nct_id>
  </id_info>
  <brief_title>Quality of Life in Patients After Combined Modality Treatment of Rectal Cancer</brief_title>
  <official_title>Quality of Life in Patients After Combined Modality Treatment of Rectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Oncology Ljubljana</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institute of Oncology Ljubljana</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is gathering informations about patients' quality of life after
      combined modality treatment of rectal cancer to evaluate how combined modality treatment for
      rectal cancer affects patients' quality of life. The findings of this study may provide us
      important information that can be used in treatment decision and to develop programs to
      improve quality of life of patients with rectal cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Over the last two decades, rectal cancer research has lead to better understanding of disease
      behaviour, resulting in more efficient treatments and higher prevalence of cancer
      survivors.Due to aggressive therapy, rectal cancer survivors can exhibit late sequelae of
      treatment, most common being impaired bowel, voiding, sexual malfunctioning and quality of
      life impairment. In order to determine the impact of rectal cancer and its treatment on
      patients' quality of life over time, this study will prospectively follow a cohort of
      patients at specified intervals evaluating their physical symptoms, physical and social
      functioning and overall quality of life.Medical and sociodemographic factors that might be
      predictive will be tested.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>January 2008</start_date>
  <completion_date type="Anticipated">September 2012</completion_date>
  <primary_completion_date type="Anticipated">September 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To prospectively evaluate the quality of life of patients one year after rectal cancer resection</measure>
    <time_frame>one year after the operation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To prospectively evaluate the quality of life of patients at baseline</measure>
    <time_frame>before treatment (at baseline)</time_frame>
    <description>consecutive patients treated winh capecitabine-based radiochemotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To prospectively evaluate the quality of life of patients two years after rectal cancer resection</measure>
    <time_frame>two years after the operation</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">167</enrollment>
  <condition>Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>rectal cancer patients</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>questionnaires</intervention_name>
    <description>Quality of life assessment using questionnaires EORTC QLQ C30 and 38 at baseline, one year and two years after the surgery of rectal cancer, treated with preoperative capecitabine based radiochemotherapy</description>
    <arm_group_label>rectal cancer patients</arm_group_label>
    <other_name>EORTC QLQ C30, EORTC QLQ C38</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        consecutive patients with rectal cancer stage II and III, treated with capecitabine-based
        preoperative radiochemotherapy from 1.1.2008 till 31.12.2009.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  histologically verified adenocarcinoma of the rectum,

          -  clinical stage II or III (IUCC TNM classification 2002);

          -  no prior radiotherapy and/or chemotherapy;

          -  World Health Organisation (WHO) performance status &lt; 2;

          -  age at diagnosis of 18 or older;

          -  and adequate bone marrow, liver, renal and cardiac function (no history of ischemic
             heart disease)

          -  mentally fit to complete questionnaires

        Exclusion Criteria:

          -  a history of prior malignancy other than non-melanoma skin cancer or in situ carcinoma
             of the cervix rendered the patient ineligible.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Institute of Oncology</name>
      <address>
        <city>Ljubljana</city>
        <zip>1000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Slovenia</country>
  </location_countries>
  <reference>
    <citation>Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993 Mar 3;85(5):365-76.</citation>
    <PMID>8433390</PMID>
  </reference>
  <reference>
    <citation>Sprangers MA, te Velde A, Aaronson NK. The construction and testing of the EORTC colorectal cancer-specific quality of life questionnaire module (QLQ-CR38). European Organization for Research and Treatment of Cancer Study Group on Quality of Life. Eur J Cancer. 1999 Feb;35(2):238-47.</citation>
    <PMID>10448266</PMID>
  </reference>
  <reference>
    <citation>Moriya Y. Function preservation in rectal cancer surgery. Int J Clin Oncol. 2006 Oct;11(5):339-43. Review.</citation>
    <PMID>17058130</PMID>
  </reference>
  <reference>
    <citation>Rauch P, Miny J, Conroy T, Neyton L, Guillemin F. Quality of life among disease-free survivors of rectal cancer. J Clin Oncol. 2004 Jan 15;22(2):354-60.</citation>
    <PMID>14722043</PMID>
  </reference>
  <reference>
    <citation>Parker PA, Baile WF, de Moor Cd, Cohen L. Psychosocial and demographic predictors of quality of life in a large sample of cancer patients. Psychooncology. 2003 Mar;12(2):183-93.</citation>
    <PMID>12619150</PMID>
  </reference>
  <reference>
    <citation>Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol. 1998 Jan;16(1):139-44.</citation>
    <PMID>9440735</PMID>
  </reference>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 25, 2010</study_first_submitted>
  <study_first_submitted_qc>June 28, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 29, 2010</study_first_posted>
  <last_update_submitted>March 23, 2012</last_update_submitted>
  <last_update_submitted_qc>March 23, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2012</last_update_posted>
  <responsible_party>
    <name_title>Proff.assist. Vaneja Velenik, MD, PhD</name_title>
    <organization>Institute of Oncology</organization>
  </responsible_party>
  <keyword>quality of life</keyword>
  <keyword>rectal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

